Company Profile

La Jolla Pharmaceutical Company is primarily engaged in the commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.

Employees

Sector

Biotechnology & Medical Research

More about the company

22/08/22	La Jolla Pharmaceutical Announces Management Changes	CI
22/08/22	La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from NASDAQ Composite Index	CI
22/08/22	La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from S&P TMI Index	CI
22/08/22	Innoviva, Inc. completed the acquisition of La Jolla Pharmaceutical Company for approximately $210 million.	CI
15/08/22	Tranche Update on La Jolla Pharmaceutical Company's Equity Buyback Plan announced on November 17, 2021.	CI
15/08/22	La Jolla Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
11/07/22	Sector Update: Health Care Stocks Edging Lower at Close	MT
11/07/22	Top Midday Gainers	MT
11/07/22	Innoviva Agrees to Take La Jolla Pharmaceutical Private in $149 Million Acquisition Deal; Shares Rise	MT
11/07/22	La Jolla Pharmaceutical Company Equity Buyback announced on November 17, 2021, has expired, in connection with the announced merger, the stock repurchase plan was cancelled effective July 11, 2022.	CI
11/07/22	Innoviva, Inc. entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company for approximately $160 million.	CI
16/05/22	La Jolla Pharmaceutical's Earnings Decline in March Quarter, Sales Increase	MT
16/05/22	Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Reports Q1 Revenue $10.4M	MT

02/08/21	La Jolla Pharmaceutical : Chardan Suspends Coverage on La Jolla Pharmaceutical at Buy Rating With $15 Price Target	MT
25/01/21	La Jolla Pharmaceutical : Chardan Adjusts La Jolla Pharmaceutical's Price Target to $15 From $20, Keeps at Buy	MT

22/08/22	La Jolla Pharmaceutical : Termination of a Material Definitive Agreement - Form 8-K	PU
22/08/22	LA JOLLA PHARMACEUTICAL CO : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
15/08/22	LA JOLLA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
12/07/22	LA JOLLA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of La Jolla Pharmaceutical Company - LJPC	BU
11/07/22	Twitter, Las Vegas Sands fall; Mullen, La Jolla rise	AQ

28/02/17	Wall St-Hausse timide à la veille du discours de Trump
28/02/17	Boeing : Wall Street termine la séance en très légère hausse à la veille du discours de Trump
28/02/17	Wall St-Hausse timide à la veille du discours de Trump

Manager	Title	Age	Since
Pavel Raifeld CEO	Chief Executive Officer	42	01/04/2023
Stephen Basso TRE	Treasurer	60	-
Katherine Dorris SEC	Corporate Secretary	-	-

La Jolla Pharmaceutical Company Stock

Stocks

LJPC

US5034596040

Biotechnology & Medical Research

Latest news: La Jolla Pharmaceutical Company

Analysts' recommendations: La Jolla Pharmaceutical Company

Press Releases: La Jolla Pharmaceutical Company

News in other languages: La Jolla Pharmaceutical Company

Managers and Directors: La Jolla Pharmaceutical Company

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
Pavel Raifeld BRD	Director/Board Member	42	22/08/2022
Stephen Basso BRD	Director/Board Member	60	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/22/22 A	Kevin Tang	Issuer sale	Chairman	142,000	0.5556%
8/22/22 A	Robert H. Rosen	Issuer sale	Director	142,000	0.5556%
8/22/22 A	Laura Douglass	Issuer sale	Director	151,000	0.5909%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LA JOLLA PHARMACEUTICAL COMPANY	-.--%	+0.48%	-	-	155M
WUXI APPTEC CO., LTD.	-2.11%	-1.68%	+43.40%	+95.58%	66.93B
ARGENX SE	+1.50%	-0.28%	+35.89%	+76.65%	61.97B
INSMED INCORPORATED	+1.67%	+2.47%	-11.32%	+392.05%	28.26B
WUXI BIOLOGICS (CAYMAN) INC.	+4.55%	+1.36%	+26.52%	+17.28%	24.59B
BIONTECH SE	+0.34%	-6.78%	-0.01%	-14.59%	24.3B
GENMAB A/S	+0.65%	-1.77%	+18.21%	-22.40%	19.41B
PHARMAESSENTIA CORPORATION	-3.03%	-2.29%	+181.72%	+333.47%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.44%	-1.88%	-5.46%	+547.21%	14.18B
SUMMIT THERAPEUTICS INC.	+3.24%	-0.31%	-7.34%	+833.51%	14B
Average	+1.24%	-2.95%	+31.29%	+250.97%	30.05B
Weighted average by Cap.	+0.84%	-2.83%	+32.11%	+173.38%